Literature DB >> 11177695

Treatment of Wilson's disease: what are the relative roles of penicillamine, trientine, and zinc supplementation?

M L Schilsky1.   

Abstract

New options are available for the medical treatment of patients with Wilson's disease. Penicillamine is no longer the treatment of choice, as there is a growing experience with safer and more effective alternatives. Trientine may be the best choice for initial therapy in symptomatic patients requiring chelation therapy, and it may be even more effective when used in combination with zinc, which is recommended for maintenance therapy. Further studies are needed to determine the best therapy for pregnant patients with Wilson's disease, and whether combination therapy using trientine and zinc will be the next treatment of choice for all symptomatic patients with liver or neurologic disease.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11177695     DOI： 10.1007/s11894-001-0041-4

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN： 1522-8037


  16 in total

1.  Wilson's disease and pregnancy.

Authors:  I Sternlieb
Journal:  Hepatology       Date:  2000-02       Impact factor: 17.425

2.  Potential hepatotoxicity of penicillamine treatment in three patients with Wilson's disease.

Authors:  J Deutscher; W Kiess; G Scheerschmidt; H Willgerodt
Journal:  J Pediatr Gastroenterol Nutr       Date:  1999-11       Impact factor: 2.839

Review 3.  ATP7B (WND) protein.

Authors:  K Terada; M L Schilsky; N Miura; T Sugiyama
Journal:  Int J Biochem Cell Biol       Date:  1998-10       Impact factor: 5.085

4.  Successful medical treatment of severely decompensated Wilson disease.

Authors:  E E Santos Silva; J Sarles; J P Buts; E M Sokal
Journal:  J Pediatr       Date:  1996-02       Impact factor: 4.406

5.  Cytopenias secondary to copper depletion complicating ammonium tetrathiomolybdate therapy for Wilson's disease.

Authors:  H Karunajeewa; A Wall; J Metz; A Grigg
Journal:  Aust N Z J Med       Date:  1998-04

6.  Prevention of Wilson's disease in asymptomatic patients.

Authors:  I Sternlieb; I H Scheinberg
Journal:  N Engl J Med       Date:  1968-02-15       Impact factor: 91.245

7.  Treatment of Wilson's disease with zinc: XV long-term follow-up studies.

Authors:  G J Brewer; R D Dick; V D Johnson; J A Brunberg; K J Kluin; J K Fink
Journal:  J Lab Clin Med       Date:  1998-10

8.  Treatment of Wilson disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy.

Authors:  G J Brewer; V Johnson; R D Dick; K J Kluin; J K Fink; J A Brunberg
Journal:  Arch Neurol       Date:  1996-10

9.  Liver transplantation for Wilson's disease: indications and outcome.

Authors:  M L Schilsky; I H Scheinberg; I Sternlieb
Journal:  Hepatology       Date:  1994-03       Impact factor: 17.425

10.  Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy.

Authors:  G J Brewer; C A Terry; A M Aisen; G M Hill
Journal:  Arch Neurol       Date:  1987-05
View more
  11 in total

1.  Methanobactin reverses acute liver failure in a rat model of Wilson disease.

Authors:  Josef Lichtmannegger; Christin Leitzinger; Ralf Wimmer; Sabine Schmitt; Sabine Schulz; Yaschar Kabiri; Carola Eberhagen; Tamara Rieder; Dirk Janik; Frauke Neff; Beate K Straub; Peter Schirmacher; Alan A DiSpirito; Nathan Bandow; Bipin S Baral; Andrew Flatley; Elisabeth Kremmer; Gerald Denk; Florian P Reiter; Simon Hohenester; Friedericke Eckardt-Schupp; Norbert A Dencher; Jerzy Adamski; Vanessa Sauer; Christoph Niemietz; Hartmut H J Schmidt; Uta Merle; Daniel Nils Gotthardt; Guido Kroemer; Karl Heinz Weiss; Hans Zischka
Journal:  J Clin Invest       Date:  2016-06-20       Impact factor: 14.808

Review 2.  Emerging Opportunities To Manipulate Metal Trafficking for Therapeutic Benefit.

Authors:  Elizabeth W Hunsaker; Katherine J Franz
Journal:  Inorg Chem       Date:  2019-06-19       Impact factor: 5.165

3.  Development of Polyamine Lassos as Polyamine Transport Inhibitors.

Authors:  Aiste Dobrovolskaite; Richard Andrew Gardner; Jean-Guy Delcros; Otto Phanstiel
Journal:  ACS Med Chem Lett       Date:  2022-01-20       Impact factor: 4.345

4.  Biocompatible D-Penicillamine Conjugated Au Nanoparticles: Targeting Intracellular Free Copper Ions for Detoxification.

Authors:  Murthi S Kandanapitiye; Chamila Gunathilake; Mietek Jaroniec; Songping D Huang
Journal:  J Mater Chem B       Date:  2015-07-21       Impact factor: 6.331

5.  Functional analysis and drug response to zinc and D-penicillamine in stable ATP7B mutant hepatic cell lines.

Authors:  Gursimran Chandhok; Judit Horvath; Annu Aggarwal; Mohit Bhatt; Andree Zibert; Hartmut Hj Schmidt
Journal:  World J Gastroenterol       Date:  2016-04-28       Impact factor: 5.742

6.  What, if anything, is specific about having a rare disorder? Patients' judgements on being ill and being rare.

Authors:  Caroline Huyard
Journal:  Health Expect       Date:  2009-10-14       Impact factor: 3.377

7.  Liver transplantation().

Authors:  M Rossi; G Mennini; Q Lai; S Ginanni Corradini; F M Drudi; F Pugliese; P B Berloco
Journal:  J Ultrasound       Date:  2007-04-16

Review 8.  Canine Models for Copper Homeostasis Disorders.

Authors:  Xiaoyan Wu; Peter A J Leegwater; Hille Fieten
Journal:  Int J Mol Sci       Date:  2016-02-04       Impact factor: 5.923

9.  Combined sodium Dimercaptopropanesulfonate and zinc versus D-penicillamine as first-line therapy for neurological Wilson's disease.

Authors:  Jing Zhang; Lulu Xiao; Wenming Yang
Journal:  BMC Neurol       Date:  2020-06-27       Impact factor: 2.474

10.  The effect of zinc and D-penicillamine in a stable human hepatoma ATP7B knockout cell line.

Authors:  Gursimran Chandhok; Nadine Schmitt; Vanessa Sauer; Annu Aggarwal; Mohit Bhatt; Hartmut H J Schmidt
Journal:  PLoS One       Date:  2014-06-03       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.